Additional immunophenotypic markers useful in lineage assignment or subtyping of AML
From haematologyetc.co.uk
These markers are not considered to define myeloid lineage, and generally have lower lineage specificity than myeloid-lineage associated markers, however they can support classification or support lineage assignment in difficult cases
| Markers that may be used to support granulocytic or monocytic maturation in AML | |
|---|---|
| These may be less specific than other markers but can be a useful adjunct in difficult cases | |
| CD11b | A marker of both granulocytic and monocytic maturation, this marker has previously been associated with less good outcome in a number of studies |
| CD11c | This marker is most associated with monocytic maturation in AML being fairly well corellated with CD11B, but overall probably less specific for monocytic differentiation that CD14
|
| Markers associated with erythroid differentiation in AML | |
|---|---|
| Most often AML with erythroid maturation will express CD34, while CD45 and HLA-DR are weak or negative. CD117 is generally expressed. There may be some expression of megkaryocytic markers in some cases. | |
| CD36 | Expression is expected, but often expressed in other subtypes so not fully lineage specific |
| CD71 | Frequently expressed though not fully lineage specific |
| CD235 | A good marker of erythroid differentiation but acquired late and therefore may not be expressed
|
| Markers associated with megakaryocytic differentiation in AML | |
|---|---|
| Most often CD34, CD45 and HLA-DR are weak or negative, although CD13 and CD33 may be expressed | |
| CD41 | Platelet glycoprotein IIbIIIa |
| CD61 | Platelet glycoprotein IIIa |
| CD36 | Relatively non-specific (seen in erythroid and monocytic leukaemias) but often strongly expressed
|